Nordic Walking as an Exercise Intervention to Reduce Pain in Women With Aromatase Inhibitor-Associated Arthralgia: A Feasibility Study.
Women taking aromatase inhibitors as treatment for breast cancer commonly experience joint pain and stiffness (aromatase inhibitor-associated arthralgia [AIAA]), which can cause problems with adherence. There is evidence that exercise might be helpful, and Nordic walking could reduce joint pain compared to normal walking.



To determine the feasibility of a trial of Nordic walking as an exercise intervention for women with AIAA.



A feasibility study was carried out in a sample of women with AIAA using a randomized control design. Women were randomized to exercise (six-week supervised group Nordic walking training once per week with an increasing independent element, followed by six weeks 4 × 30 minutes/week independent Nordic walking); or enhanced usual care. Data were collected on recruitment, retention, exercise adherence, safety, and acceptability. The Brief Pain Inventory, GP Physical Activity Questionnaire, and biopsychosocial measures were completed at baseline, six and 12 weeks.



Forty of 159 eligible women were recruited and attrition was 10%. There was no increased lymphedema and no long-term or serious injury. Adherence was >90% for weekly supervised group Nordic walking, and during independent Nordic walking, >80% women managed one to two Nordic walking sessions per week. From baseline to study end point, overall activity levels increased and pain reduced in both the intervention and control groups.



Our findings indicate that women with AIAA are prepared to take up Nordic walking, complete a six-week supervised course and maintain increased activity levels over a 12-week period with no adverse effects.
Poole Hospital NHS Foundation Trust, Poole, Wales, United Kingdom; University of Southampton, Southampton, Wales, United Kingdom. Electronic address: Jo.fields@poole.nhs.uk.
Jo
J
Fields
University of Southampton, Southampton, Wales, United Kingdom; University Hospital Southampton NHS Foundation Trust, Southampton, Wales, United Kingdom.
Alison
A
Richardson
Cardiff University, Cardiff, Wales, United Kingdom.
Jane
J
Hopkinson
University of Southampton, Southampton, Wales, United Kingdom; University Hospital Southampton NHS Foundation Trust, Southampton, Wales, United Kingdom.
Deborah
D
Fenlon
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D005081:Exercise Therapy; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000503:physiopathology; D059408:Pain Management; D010349:Patient Compliance; D017060:Patient Satisfaction; D016896:Treatment Outcome; D016138:Walking
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors
Feasibility trial; Nordic walking; aromatase inhibitor–associated arthralgia; breast cancer; exercise; joint pain